Health
Cerevel CEO Tony Coles Steps Down From Neuroscience Biotech
- Bain Partner, former Translate Bio CEO will replace Coles
- Coles to leave CEO post in June, to remain board chairman
This article is for subscribers only.
Cerevel Therapeutics Holdings Inc. Chief Executive Officer Tony Coles, 62, will step down next month after four years at the helm of the neuroscience drugmaker, which has faced delays in developing new treatments.
Coles, a longtime biotech executive, will be replaced by Ron Renaud, a partner at Bain Capital Life Sciences and former CEO of Translate Bio, an mRNA company that was acquired by Sanofi in 2021. Renaud, 54, will leave Bain in May and start at Cerevel in June.